GMAB vs REGN vs SRPT vs INCY vs EXEL

For growth investors, Incyte Corporation (INCY) is the stronger pick with 21.

2% revenue growth year-over-year, versus -82. 7% for Genmab A/S (GMAB). Incyte Corporation (INCY) offers the better valuation at 15. 3x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Genmab A/S (GMAB) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.

3x versus Genmab A/S at 17. 6x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 6. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Exelixis, Inc. wins at 0. 27x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +84. 0%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: EXEL returned +833. 5% versus SRPT's +18. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exelixis, Inc.

(EXEL) is the lower-risk stock at 0. 80β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 153% more volatile than EXEL relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 93% for Genmab A/S — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Incyte Corporation (INCY) is pulling ahead at 21.

2% versus -82. 7% for Genmab A/S (GMAB). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37. 6% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Exelixis, Inc. (EXEL) is the more undervalued stock at a PEG of 0. 27x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Sarepta Therapeutics, Inc. (SRPT) trades at 6. 9x forward P/E versus 23. 3x for Genmab A/S — 16. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMAB: 47. 5% to $39. 90.

In this comparison, REGN (0.

5% yield) pays a dividend. GMAB, SRPT, INCY, EXEL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exelixis, Inc.

(EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80), +833. 5% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXEL: +833. 5%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GMAB is a mid-cap deep-value stock; REGN is a mid-cap deep-value stock; SRPT is a small-cap high-growth stock; INCY is a mid-cap high-growth stock; EXEL is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.